Controversy remains over ‘pay for delay’

A tactic used in some drug patent settlement cases is creating renewed controversy concerning so-called “pay for delay” agreed between GlaxoSmithKline and Dong-A, which was made public by the Fair Trade Commission Thursday.

However, GSK said Thursday that it did not make any agreements with Dong-A Pharmaceutical over “pay for delay”, saying it will clarify this to the forthcoming FTC meeting...